Asensus Surgical announced that it has received 510(k) clearance from the FDA for an expanded indication to treat pediatric patients with the Senhance System. The Senhance System is already approved for pediatric patients in the EU and Japan.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASXC:
- Asensus Surgical Receives FDA 510(k) Clearance For Pediatric Indication for Senhance Surgical System
- Asensus Surgical to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Asensus Surgical price target lowered to $2 from $3 at H.C. Wainwright
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2022
- Asensus Surgical, Inc. to Release Fourth Quarter and Full Year 2022 Financial and Operating Results on March 2, 2023